Bone's Technology Secures Tens of Millions in Series A Funding Led by Sequoia China to Advance Smart Orthopedic Solutions

VCBeat has learned that, recently,Pioneer in Intelligent Orthopedic Diagnosis and Treatment Systems—Bozhi Biology Announces Completion of Multi-Million Dollar Series A Financing.This funding round was led by Sequoia China, with continued support from existing investors such as Shukun Technology, MiraclePlus, and HKX Fund.It has been revealed that Bozhi Biotech has officially launched its Pre-B financing round, with plans to complete it in the first quarter.

Source: Bozhi Biotech

The funds raised in this round will be primarily used to accelerate the research-to-commercialization translation of its product portfolio, including intelligent orthopedic robots and drug-eluting implants; to fully advance clinical trials and domestic and international regulatory registrations for several Class III medical devices; to rapidly increase market penetration; and to establish a nationwide marketing channel across China., to bring better treatment options to the vast number of orthopedic patients in China, especially elderly orthopedic patients, at an early date.

Bozhi Biologics, founded in 2018 and headquartered in Hong Kong, China, is committed to helping humanity prevent and treat skeletal system diseases through innovative technologies that integrate digitalization with combined pharmaceutical and medical device solutions. The company’s vision is to ensure healthy and strong bones for every elderly individual, driving the intelligent transformation and upgrading of orthopedic diagnosis, treatment, prevention, and control through an integrated product matrix encompassing “brain, eye, hand, and device” capabilities. Currently in a phase of rapid growth, Bozhi Biologics has completed the research, development, and regulatory registration of its integrated digital orthopedic diagnosis and treatment system, and has initiated clinical trials and global regulatory submissions for its comprehensive product portfolio, which includes the world’s first integrated orthopedic diagnosis and treatment system, an intelligence-enabled force-controlled orthopedic robot, drug-eluting bone implants, and preventive screening products.

Source: Bozhi Biopharma

Nearly 30 years of accumulated research and clinical experience in orthopedics is one of Bozhi Bio’s unique differentiated advantages.The team’s core technical members include professors and PhDs with international professional backgrounds from institutions such as the Department of Orthopaedics and Traumatology at The University of Hong Kong and the University of Oxford. Its co-founder, Professor Lu Weijia, is a world-renowned orthopedic scientist who founded the Orthopaedic Research Centre at The University of Hong Kong, served as Chair of the International Bone Research Association Conference, President of the Hong Kong Society for Biomedical Engineering, and Principal Investigator of China’s National Key R&D Program (the first in Hong Kong). He was ranked among the top 1% of scientists worldwide by ISI for ten consecutive years (2009–2018).

Academician Liang Zhiren, a member of the clinical expert advisory team, provided in-depth guidance on Bozhi Biologics’ industrialization strategy. Professor Liang is the first scholar from Hong Kong, China, to be elected as an Academician of the Chinese Academy of Sciences based on his medical achievements. He enjoys international renown for his clinical research in spinal surgery and pediatric orthopedics. He served as President of the Société Internationale de Chirurgie Orthopédique et de Traumatologie (SICOT) from 2002 to 2005, becoming the first person of Chinese descent to hold this position in the nearly 80 years since the society’s founding in Paris.

Bozhi Biotech not only boasts a robust technical team but also an exceptional marketing force.Senior experts from renowned medical device companies, both domestic and international, such as Medtronic and Johnson & Johnson, possess extensive experience in the field of orthopedic robotics and consumables. They also have nationwide medical and distributor resources, providing significant advantages in expanding customer bases and broadening sales channels.

Dr. Ma Chi, CEO of Bozhi Biotech, stated:“We extend our gratitude to Sequoia Capital China and other leading professional investment institutions, including our existing shareholders, for their recognition of Bozhi Biotechnology. We also express special appreciation to Professor Li Zexiang of the HKX Fund for his invaluable guidance on industrialization throughout Bozhi Biotechnology’s development journey. Building upon three decades of scientific research and practical experience, Bozhi Biotechnology has identified critical clinical pain points and developed digital technologies—an achievement affirmed by many esteemed pioneers, including Academician Leung Chi Yan. In the coming years, the company will remain steadfast in its customer-centric culture of innovation, maintaining close engagement with frontline clinical practice. Leveraging digital orthopedic technologies, we aim to reshape the orthopedic healthcare market, empowering physicians with greater confidence to partner with us in safeguarding public health and ensuring healthy bones for every elderly individual.”

Xu Qiang, Managing Director of Sequoia China, stated:“Sequoia China has been committed to helping innovative medical device companies grow rapidly, and orthopedic diagnosis and treatment is one of our key focus areas. With the development of technologies such as precision medicine, 3D printing, and artificial intelligence, a wave of digitalization and intelligence in orthopedics has emerged. We highly recognize Bozhi Biotechnology’s R&D capabilities and its ability to identify and address clinical pain points. We also look forward to the company achieving more innovative breakthroughs in this trend, thereby benefiting more orthopedic patients.”

Ma Chun'e, Founder and CEO of Shukun Technology, stated:“Bozhi Biotechnology’s strategic entry into the digital orthopedics sector demonstrates remarkable foresight. By enabling orthopedic surgeons to deliver more precise, personalized, and optimized therapeutic outcomes, Bozhi Biotechnology significantly reduces the incidence of postoperative complications. The comprehensive intelligentization of imaging diagnosis and surgical workflows represents a major trend in the healthcare industry. We look forward to Bozhi Biotechnology’s continued efforts and innovation in accelerating the digital transformation of the orthopedics sector, thereby making greater contributions to human skeletal health and the high-quality development of the medical and healthcare industry.”

Mao Shengbo, Partner at MiraclePlus, stated:“We are highly optimistic about the broader trend of digitalization in orthopedics, as well as about Bozhi Bio’s team, which combines deep scientific research expertise with dynamic energy. Bozhi Bio has successfully developed a world-leading bone quality assessment system that significantly improves the accuracy of traditional testing methods. The company has already established collaborations with dozens of hospitals, including Queen Mary Hospital in Hong Kong and Peking Union Medical College Hospital in Beijing. Its all-in-one digital orthopedic diagnosis and treatment device has been used clinically in nearly 10,000 cases, demonstrating the feasibility of rapid commercial implementation.”

Professor Chen Guanhua, Co-Founder of HKX Fund, stated:“Starting from the university ecosystem, HKX helps promising alumni teams and top-tier research groups expand from Hong Kong universities into the vast mainland China market. We are highly optimistic about Bozhi Biotech, founded by medical professors and PhDs from The University of Hong Kong. The Bozhi Biotech team possesses exceptional international vision and execution capabilities. As a practitioner of intelligent orthopedic innovation within Hong Kong’s medtech ecosystem, it is committed to facilitating healthcare upgrades throughout the entire diagnostic and therapeutic process. We believe that Bozhi Biotech will continue to drive technological innovation, co-build the Greater Bay Area’s medtech ecosystem, and provide innovative diagnostic and therapeutic equipment as well as medical materials to meet healthcare needs in the context of an aging population.”

Including this round of financing, Bozhi Biologics has received investments from Sequoia China, HKX Fund, MiraclePlus, and Shukun Technology, as well as research funding support from the Innovation and Technology Commission of Hong Kong and industrial linkage resources provided by the Hong Kong Science Park. The company has also benefited from platform resource support offered by the Shenzhen Municipal Science and Technology Innovation Commission, the Qianhai Authority, and the Qianhai Shenzhen-Hong Kong Youth Dream Factory. Joseph, a partner at Global Law Firm, served as legal counsel for this financing round.

Sequoia China is committed to helping entrepreneurs build enduring, great companies by bringing abundant global resources and valuable historical experience to its portfolio companies. As “entrepreneurs behind entrepreneurs,” Sequoia China focuses on investment opportunities in technology, consumer, and healthcare sectors. Over the past 17 years, Sequoia China has invested in more than 900 companies with distinct technological features, innovative business models, high growth potential, and strong development prospects.

Shukun Technology is a leading platform enterprise in the field of medical artificial intelligence, recognized as both a National High-Tech Enterprise and a Zhongguancun High-Tech Enterprise. Shukun Technology has independently developed and pioneered its suite of “Digital Doctor” products, including “Digital Heart,” “Digital Brain,” “Digital Lung,” “Digital Abdomen,” and “Digital Musculoskeletal,” providing intelligent diagnostic and therapeutic solutions for major critical diseases such as heart disease, stroke, and cancer. Currently, Shukun’s Digital Doctor products have been adopted and installed in over 1,600 hospitals across China. The company has also established a strategic partnership with Meinian Onehealth Healthcare to promote the implementation of initiatives such as “combined heart and lung screening” in health examination institutions. Furthermore, Shukun Technology has formed a partnership with Bozhi Bio, another intelligent healthcare enterprise, to jointly advance into the era of digital orthopedics and deliver superior diagnostic and treatment services to orthopedic patients in China. This collaboration is expected to have a profound impact on the market strategies of both parties.

MiraclePlus was founded in 2018 by Dr. Qi Lu. Its predecessor was YC China (YC is a world-leading early-stage investment accelerator, with its portfolio companies valued at over $300 billion; it served as the initial investor for nearly 30 unicorns, including Airbnb and Dropbox). The MiraclePlus team localized YC’s proven “investment + acceleration” model from the U.S., and within two years of operation, has invested in nearly 100 startups. These ventures span 15 frontier sectors, including brain-computer interfaces, nanotechnology, aerospace, autonomous driving, cloud gaming, and new consumer trends.

Co-founded in Hong Kong by Mr. Neil Shen, Global Executive Partner of Sequoia Capital China and member of the 13th National Committee of the Chinese People's Political Consultative Conference; Professor Zexiang Li, Chairman of DJI Innovations and professor at the Hong Kong University of Science and Technology; and Professor Guan-Hua Chen from the University of Hong Kong, together with 22 renowned professors and technology elites from Hong Kong. The HKX Fund focuses on investing in early-stage technology startups in Hong Kong and the Guangdong-Hong Kong-Macao Greater Bay Area, with key sectors including big data and artificial intelligence, microelectronics and chip design, robotics and intelligent manufacturing, biotechnology, healthcare and pharmaceuticals, advanced materials, and fintech.

Bozhi Biotechnology Co., Ltd. specializes in providing digital diagnostic and therapeutic solutions for orthopedics to physicians and patients. Leveraging nearly 30 years of specialized research expertise from the Orthopaedic Laboratory of The University of Hong Kong, and integrating biomechanics, clinical big data, and artificial intelligence technologies, the company has developed a range of intelligent orthopedic diagnostic and therapeutic devices, including intelligent diagnostic software, surgical robots, and personalized consumables, with the commitment to building a one-stop product portfolio for orthopedic diagnosis and treatment.